Tamoxifen appears to reduce the risk of benign breast disease and may result in fewer biopsies, according to an analysis of data from a major randomized clinical trial of tamoxifen. The findings appear in the February 19 issue of the Journal of the National Cancer Institute.
Tamoxifen was shown in the Breast Cancer Prevention Trial to reduce the incidence of invasive and noninvasive breast cancer by as much as 50% compared to placebo. Other studies have suggested that tamoxifen can also decrease the size of benign breast lesions, which have been associated with a modest increase in the risk for developing invasive breast cancer.
To examine the effect of tamoxifen on the risk of developing benign breast lesions, Elizabeth Tan-Chiu, M.D., of the Cancer Research Network in Plantation, Fla., and her coworkers from the National Surgical Adjuvant Breast and Bowel Project examined the incidence of benign breast disease among 13,203 women treated with either tamoxifen or a placebo as part of the Breast Cancer Prevention Trial. The authors also noted how many biopsies each group of women underwent.
Linda Wang | EurekAlert!
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy